Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group (Q31440445)

2 July 2017

title

Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group (English)

1 reference

multicenter clinical trial

2 July 2017

0 references

0 references

author name string

J Ishigooka

series ordinal

1 reference

2 July 2017

M Murasaki

series ordinal

1 reference

2 July 2017

S Miura

series ordinal

1 reference

2 July 2017

publication date

1 August 2000

1 reference

Psychiatry and Clinical Neurosciences

2 July 2017

published in

1 reference

2 July 2017

1 reference

2 July 2017

1 reference

2 July 2017

page(s)

467-478

1 reference

Radioreceptor binding profile of the atypical antipsychotic olanzapine

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

The analysis of a titration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

Weight gain associated with neuroleptic medication: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

Clozapine-induced weight gain: prevalence and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1819.2000.00738.X

10.1046/J.1440-1819.2000.00738.X

21 January 2018

Identifiers

DOI

1 reference

2 July 2017

1 reference